Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5285127
Max Phase: Preclinical
Molecular Formula: C25H30O13
Molecular Weight: 538.50
Associated Items:
ID: ALA5285127
Max Phase: Preclinical
Molecular Formula: C25H30O13
Molecular Weight: 538.50
Associated Items:
Canonical SMILES: C/C=C1\C2CC(=O)OC[C@@H](c3ccc(O)c(O)c3)OC[C@H]3O[C@@H](O[C@@H]1OC=C2C(=O)OC)[C@H](O)[C@@H](O)[C@@H]3O
Standard InChI: InChI=1S/C25H30O13/c1-3-12-13-7-19(28)35-9-17(11-4-5-15(26)16(27)6-11)34-10-18-20(29)21(30)22(31)25(37-18)38-24(12)36-8-14(13)23(32)33-2/h3-6,8,13,17-18,20-22,24-27,29-31H,7,9-10H2,1-2H3/b12-3+/t13?,17-,18+,20+,21-,22+,24-,25-/m0/s1
Standard InChI Key: QVUZRUJONIJRDT-IEYFBXSNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 538.50 | Molecular Weight (Monoisotopic): 538.1686 | AlogP: -0.10 | #Rotatable Bonds: 2 |
Polar Surface Area: 190.67 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 9.21 | CX Basic pKa: | CX LogP: 0.35 | CX LogD: 0.35 |
Aromatic Rings: 1 | Heavy Atoms: 38 | QED Weighted: 0.19 | Np Likeness Score: 1.78 |
1. Bi Y, Wang X, Han L, Tian Y, Bo T, Li C, Shi B, Gui C, Zhang Y.. (2023) Selective Inhibition of Organic Cation Transporter 1 by Benzoylpaeoniflorin Attenuates Hepatic Lipid Accumulation through AMPK Activation., 86 (1.0): [PMID:36563333] [10.1021/acs.jnatprod.2c00927] |
Source(1):